²é¿´: 924  |  »Ø¸´: 1
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

xing2007

½ð³æ (³õÈëÎÄ̳)

[½»Á÷] Ó¢Ò뺺-Ò©Àí

The  processes  involved  in  mammalian  reproduction,  from ovulation  through  to  birth,  clearly  involve  large-scale  tissue remodelling, with some close analogies to in fl ammatory processes. One such process is the rupture of the ovarian follicle on ovulation. Human follicular fl uid has been found to contain heparan sulphate
with unusually strong anticoagulant activity, due to a high content of 3-O-sulphated glucosamine [49]. Indeed, mice lacking the 3-O- sulfotransferase enzyme were found to have normal haemostasis but exhibited reproductive abnormalities [50]. Protracted labour is one of the major reasons for emergency caesarean section. Through clinical observations that women who were undergoing low molecular heparin treatment for thrombophilia had shorter labour time and experimental fi ndings that low molecular weight heparin increases myometrial contractility and induces increased synthesis of interleukin 8 in cervical fi broblasts
[51], a non-anticoagulant heparin is now in Phase I clinical trial for the  prevention  and  treatment  of  protracted  labour  [52].  The mechanism by which heparin acts in this indication is unclear. Human cervical ripening and cervical dilation is known to be a proinflammatory event [53,54] and heparin may have an effect on this process.
Thrombosis is often associated with aggressive cancers such as pancreatic cancer and there are numerous clinical trials investigating the effect of heparin and low molecular weight heparin on the morbidity and mortality rate of cancer patients. Meta-analysis has shown that heparin therapies do improve survival rate for this
group of patients. In addition, there is evidence to show that apart from acting as an antithrombotic, heparin may also possess antineoplastic properties. In cell based and animal models, Mellor et al.[55]  demonstrated  that  non-anticoagulant  heparin  signi fi cantly inhibits the migration of breast cancer cells and that anticoagulant heparin can reduce migration and metastatic spread of cancer cells.
The anti-metastatic effect may be due to its ability to inhibit the binding  of  growth  factor  on  cell  surface,  leading  to  inhibition of angiogenesis. Heparin can also inhibit the adhesion by acting on L- and P-selectin [56]
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zhangzhiweia

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

xing2007(½ð±Ò+8, ·­ÒëEPI+1):лл 2010-08-23 07:39:50
ÔÚ²¸È鶯Îï·±Ö³ËùÉæ¼°µÄ¹ý³Ì£¬´Ó³öÉúÒ»Ö±µ½ÅÅÂÑ£¬Ã÷È·Éæ¼°´ó¹æÄ£×éÖ¯ÖØ¹¹£¬ÔÚ·ðÂÞÀï´ïÖݵÄһЩammatory½ø³ÌÃÜÇÐÀà±È¡£ÕâÑùÒ»¸ö¹ý³ÌÊǶÔÅÅÂÑÂÑÅÝÆÆÁÑ¡£ÈËÀàÂËÅÝ·ðÂÞÀï´ïÖݵÄuidÒÑ·¢ÏÖº¬ÓÐÁòËáÒÒõ£¸ÎËØÓëÒ쳣ǿ´óµÄ¿¹ÄýѪ»îÐÔ£¬ÓÉÓÚ3 - OÐÍÁòËá°±»ùÆÏÌÑÌǺ¬Á¿¸ß[49]¡£ÊÂʵÉÏ£¬Ð¡Êóȱ·¦3 - OÐÍת»Çøø±»·¢ÏÖÓÐÕý³£Ö¹Ñª£¬µ«Õ¹³öµÄÉúÖ³Òì³£[50]¡£¿õÈճ־õÄÀͶ¯ÊÇΪ½ô¼±ÆÊ¸¹²úµÄÖ÷ÒªÔ­ÒòÖ®Ò»¡£ ͨ¹ý¸Ã¸¾Å®Ë­ÕýÔÚ¾­ÀúµÍ·Ö×ÓÁ¿¸ÎËØÖÎÁƶÔѪ˨ÐγÉÀͶ¯Ê±¼ä½Ï¶ÌºÍʵÑ飬µÍ·Ö×ÓÁ¿¸ÎËØÔö¼Ó×Ó¹¬ÊÕËõ£¬²¢¿Éʹ¹¬¾±°©¿Æ»ÃbroblastsÔö¼Ó°×ϸ°û½éËØ-8µÄºÏ³É¿Æ»ÃndingsÁÙ´²¹Û²ì
[51]£¬·Ç¸ÎËØ¿¹ÄýѪ¼ÁÊÇĿǰÔÚµÚÒ»½×¶ÎµÄÔ¤·ÀºÍÖÎÁƵÄÁÙ´²ÊÔÑéµÄ³¤ÆÚÀͶ¯[52]¡£ÕâÒ»»úÖÆµÄÐÐΪ£¬ÔÚ´ËÊÊÓ¦Ö¢¸ÎËØÄ¿Ç°»¹²»Çå³þ¡£¹¬¾±°©ºÍ¹¬¾±À©ÕųÉÊ죬±»³ÆÎªÊÇÒ»¸öÑ×ÐÔʼþ[53,54]ºÍ¸ÎËØ¿ÉÄܶÔÕâÒ»¹ý³ÌµÄÓ°Ïì¡£
Ѫ˨ÍùÍùÊÇÏà¹ØµÄ£¬ÈçÒÈÔà°©ÇÖÂÔÐÔ°©Ö¢£¬¶øÓÖÓкܶàµ÷²é¸ÎËØºÍºÜµÍµÄ·¢²¡ÂʺÍËÀÍöÂʵݩ֢»¼ÕßÐÄÂÊ·Ö×ÓÁ¿¸ÎËØµÄÁÙ´²ÊÔÑé¡£ Meta·ÖÎö±íÃ÷£¬¸ÎËØÖÎÁƲ»¸ÄÉÆÕâ¸ö´æ»îÂÊ×鲡ÈË¡£´ËÍ⣬ÓÐÖ¤¾Ý±íÃ÷£¬³ýÁË×÷ΪһÖÖ¿¹ÑªË¨Ðγɣ¬Ò²¿ÉÄܾßÓиÎËØµÄ¿¹Ö×Áö×÷ÓõÄÊôÐÔ¡£ÔÚϸ°ûºÍ¶¯ÎïÄ£ÐÍΪ»ù´¡£¬Ã·ÀÕµÈÈË¡£ [55]±íÃ÷£¬·Ç¿¹ÄýѪ¼Á¸ÎËØÕÒ³öËùÓпƻÃÎü¹â¶ÈÒÖÖÆÈéÏÙ°©Ï¸°ûµÄÇ¨ÒÆºÍ¿¹ÄýѪ¼Á¸ÎËØ¿ÉÒÔ½µµÍÒÆÖ²°©Ï¸°ûµÄ×ªÒÆºÍÀ©É¢¡£
¿¹Ö×Áö×ªÒÆ×÷ÓÿÉÄÜÊÇÓÉÓÚËüÄܹ»ÒÖÖÆÉú³¤Òò×Ó¶Ôϸ°û±íÃæ½áºÏ£¬µ¼ÖÂѪ¹ÜÉú³ÉµÄÒÖÖÆ×÷Ó᣸ÎËØ»¹¿ÉÒÔÒÖÖÆ¶ÔL -¼°P -Ñ¡ÔñËØ[56]µÄÕ³¸½×÷ÓÃ
2Â¥2010-08-22 07:49:03
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ xing2007 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ¹¤¿Æ²ÄÁÏ085601 279Çóµ÷¼Á +6 À§ÓÚÐdz¿ 2026-03-17 7/350 2026-03-20 10:48 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] Ò»Ö¾Ô¸Ìì½ò´óѧ»¯Ñ§¹¤ÒÕרҵ£¨081702£©315·ÖÇóµ÷¼Á +11 yangfz 2026-03-17 11/550 2026-03-19 15:06 by houyaoxu
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +7 Ϊѧ666 2026-03-16 7/350 2026-03-19 14:48 by ¾¡Ë´Ò¢1
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á +5 pupcoco 2026-03-17 8/400 2026-03-19 13:58 by houyaoxu
[¿¼ÑÐ] Ò»Ö¾Ô¸985£¬±¾¿Æ211£¬0817»¯Ñ§¹¤³ÌÓë¼¼Êõ319Çóµ÷¼Á +10 Liwangman 2026-03-15 10/500 2026-03-19 10:25 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 274Çóµ÷¼Á +6 S.H1 2026-03-18 6/300 2026-03-19 09:34 by »¨µêÏà¼û
[¿¼ÑÐ] ¡¾Í¬¼ÃÈí¼þ¡¿Èí¼þ£¨085405£©¿¼ÑÐÇóµ÷¼Á +3 2026eternal 2026-03-18 3/150 2026-03-18 19:09 by ²«»÷518
[¿¼ÑÐ] Ò»Ö¾Ô¸ÎäÀí²ÄÁÏ305·ÖÇóµ÷¼Á +5 ÏëÉϰ¶µÄÀðÓã 2026-03-18 6/300 2026-03-18 17:53 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] »¯Ñ§¹¤³Ì321·ÖÇóµ÷¼Á +15 ´óÃ×·¹£¡ 2026-03-15 18/900 2026-03-18 14:52 by haxia
[¿¼ÑÐ] ÉúÎïѧ071000 329·ÖÇóµ÷¼Á +3 ÎÒ°®ÉúÎïÉúÎﰮΠ2026-03-17 3/150 2026-03-18 10:12 by macy2011
[¿¼ÑÐ] 268Çóµ÷¼Á +6 ¼òµ¥µã0 2026-03-17 6/300 2026-03-18 09:04 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 293Çóµ÷¼Á +11 zjlµÄºÅ 2026-03-16 16/800 2026-03-18 08:10 by zhukairuo
[¿¼ÑÐ] 268Çóµ÷¼Á +8 Ò»¶¨ÓÐѧÉÏ- 2026-03-14 9/450 2026-03-17 17:47 by laoshidan
[¿¼ÑÐ] 308Çóµ÷¼Á +4 ÊÇLupa°¡ 2026-03-16 4/200 2026-03-17 17:12 by ruiyingmiao
[¿¼ÑÐ] 283Çóµ÷¼Á +3 Ìý·ç¾ÍÊÇÓꣻ 2026-03-16 3/150 2026-03-17 07:41 by ÈÈÇéɳĮ
[¿¼ÑÐ] ҩѧ383 Çóµ÷¼Á +3 ҩѧchy 2026-03-15 4/200 2026-03-16 20:51 by Ôª×Ó^0^
[¿¼ÑÐ] 304Çóµ÷¼Á +3 ÂüÊâ2266 2026-03-14 3/150 2026-03-16 16:39 by houyaoxu
[¿¼ÑÐ] ÖпÆÔº²ÄÁÏ273Çóµ÷¼Á +4 yzydy 2026-03-15 4/200 2026-03-16 15:59 by Gaodh_82
[¿¼ÑÐ] ±¾¿ÆÄϾ©´óѧһ־Ը´¨´óҩѧ327 +3 ÂóÌï¸ûÕß 2026-03-14 3/150 2026-03-14 20:04 by ÍâÐÇÎÄÃ÷
[¿¼ÑÐ] Ò»Ö¾Ô¸¹þ¹¤´ó²ÄÁÏ324·ÖÇóµ÷¼Á +5 ãÆÐñ¶« 2026-03-14 5/250 2026-03-14 14:53 by ľ¹Ï¸à
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û